SS Innovations International (NASDAQ: SSII) Turning India’s Surgical Robotics Opportunity Into a Global Growth Story

SS Innovations is scaling its SSi Mantra surgical robotic system from an established Indian base into international markets.
Second-quarter revenue rose 39.4% year over year to $13.9 million, while 30 SSi Mantra systems were installed during the quarter.
The company entered the second half of 2026 with 224 systems installed across 12 countries and more than 12,000 cumulative procedures.
Potential regulatory clearance in the United States and CE marking in Europe could materially enlarge SSII’s addressable market.
The investment case is seen as attractive because SSII is still early in its commercialization curve, although investors must weigh cash consumption, regulatory risk, and potential dilution against its growth prospects.

SS Innovations International (NASD AQ: SSII), a developer of innovative surgical robotic technologies, presents an attractive proposition for investors in the medical-technology sector. The company’s SSi Mantra system is being deployed at an increasing number of hospitals, surgeons are performing thousands of procedures with the platform, and SSII is beginning to establish an installed base outside its home market.

At a glance

Company: SS Innovations International
Ticker: NASDAQ: SSII
Announcement: Expansion

Key figures

Second-quarter revenue: $13.9 million
Year-over-year revenue increase: 39.4%
Systems installed during the quarter: 30
Systems installed across countries at the start of the second half of 2026: 224 across 12 countries
Cumulative procedures: more than 12,000

Products and programs

SSi Mantra surgical robotic system

The latest quarterly figures show a company rapidly expanding from a relatively small original base. SSII reported second-quarter revenue of $13.9 million, an increase of 39.4% from the same period a year earlier. It installed 30 SSi Mantra systems during the…

Questions around this news

What were SS Innovations’ second-quarter revenue and system installation figures?
The company reported revenue of $13.9 million for the quarter, representing a 39.4% increase compared with the same quarter a year earlier. It also placed 30 SSi Mantra systems during that period. These figures describe reported quarterly results; they do not, on their own, indicate how future revenue or installations will develop.
How widely is the SSi Mantra system deployed, and how many procedures have been performed?
At the beginning of the second half of 2026, the company reported 224 systems deployed in 12 countries. It also said that more than 12,000 procedures had been completed using the platform cumulatively. Those are company-reported milestones in the release and provide a snapshot of its reach and use at that time.
What regulatory milestones could open additional markets for the surgical robot?
The release identifies possible U.S. regulatory clearance and European CE marking as milestones that could expand the markets available to the company. It presents both as potential developments, not approvals already received. The release provides no timing or assurance that either authorization will be granted, so the opportunity remains subject to regulatory decisions.

SEC filings

Earlier from SS Innovations International

Back to News Center

SS Innovations International (NASDAQ: SSII) Turning India’s Surgical Robotics Opportunity Into a Global Growth Story